|
THE COST-EFFECTIVENESS OF PHARMACEUTICAL CARE TO SLOW PROGRESSION OF THE KIDNEY IN CHRONIC KIDNEY DISEASE WITH DIABETES PATIENTS AT LAEM CHABANG HOSPITAL, CHONBURI PROVINCE |
|---|---|
| รหัสดีโอไอ | |
| Creator | Orathai Pattanamongkol, Dusit Chantaracha, Rapeepun Chalongsuk, Manat Pongchaidecha, Daraporn Rungprai ,Suthabordee Muongmee |
| Title | THE COST-EFFECTIVENESS OF PHARMACEUTICAL CARE TO SLOW PROGRESSION OF THE KIDNEY IN CHRONIC KIDNEY DISEASE WITH DIABETES PATIENTS AT LAEM CHABANG HOSPITAL, CHONBURI PROVINCE |
| Publisher | Faculty of Pharmacy, Silpakorn University |
| Publication Year | 2561 |
| Journal Title | Thai Bulletin of Pharmaceutical Science (TBPS) |
| Journal Vol. | 13 |
| Journal No. | 1(January-June) |
| Page no. | 53-67 |
| Keyword | cost-effectiveness, pharmaceutical care, slow progression of the kidney disease, diabetes |
| URL Website | https://www.tci-thaijo.org/ |
| ISSN | 1686-9540 |
| Abstract | This study was a randomized control trial to compare the cost-effectiveness of pharmaceutical care on delaying the progression of renal insufficiency among patients with CKD and Type 2 diabetes at Laem Chabang Hospital. The data were collected from April, 2016 to March, 2017. Eligible patients (n = 168) were randomly allocated to either the structured care (SC) group (n = 83) or the usual care (UC) group (n = 85). The results showed that the estimated glomerular filtration rate and urine albuminuria values in both SC and UC groups were not statistically significant (p = 0.73, p = 0.08),but in the SC group greater numbers of DRPs were found and solved (58.89, 43.18 percent). The results of the cost-effectiveness analysis showed that the total cost of the SC group was 215,016 Baht with an average cost of 2,590.55 Baht per case. Meanwhile, the total cost of the UC group was 198,822 Baht with an average cost of 2,339.08 Baht per case. The SC group and UC group showed a cost-effectiveness ratio considering the number of patients with constant or increased eGFR changes of 4,134.92 and 4,142.13 respectively, and when considering the number of patients with decreased ACR changes, the values were 3,359.63 and 4,142.13 respectively. The results of incremental cost-effectiveness ratio showed that when effectiveness was measured by the number of patients with constant or increased eGFR changes, the number of patients with decreased ACR changes and the number of DRPs found and solved, the figures were 4,048.5 Baht/patient, 1,012.13 Baht/patient and 108.62 Baht/DRP respectively). In conclusion, the pharmaceutical care program with the multidisciplinary team was more cost-effective in delaying the progression of renal insufficiency. |
